GABORONE — Botswana has approved the use of injectable anti-retroviral (ARV) drugs to improve adherence to HIV treatment. Minister of Health Edwin Dikoloti says the injections, given every two months, are more convenient than daily pills, which patients sometimes skip.
Health Minister Edwin Dikoloti said the use of injectable ARV medication will start next year, after the recent approval of the drug.
“(The) government is working on introducing the injectable anti-retroviral medication soon. Botswana has, through the professional guidance of the clinical guidelines committee, adopted the use of injectable antiretroviral medicines given every two months, for both prevention and treatment,” said Dikoloti.
Minister Dikoloti said the move will help alleviate concerns that patients are skipping their daily oral dose.
“The injectable ARVs, for both prevention and treatment, will no doubt improve adherence to the HIV treatment in our country. The injectable ARV medication formula comprises cabotegravir and rilpivirine. The cabotegravir injection has already been registered by the Botswana Medicines Regulatory Authority while rilpivirine is still undergoing the registration process,” said Dikoloti.
“The injectable ARVs, for both prevention and treatment, will no doubt improve adherence to the HIV treatment in our country. The injectable ARV medication formula comprises cabotegravir and rilpivirine. The cabotegravir injection has already been registered by the Botswana Medicines Regulatory Authority while rilpivirine is still undergoing the registration process.”Edwin Dikoloti, Minister of Health
HIV activist Bonosi Bino Segadimo said the introduction of injectable medication will not only help with compliance but could reduce the stigma associated with the virus that causes AIDS.
“I believe the injectable ARVs will help a lot of people in terms of adherence because a lot of defaulting is caused by taking a pill every day. Some say the bottles (for oral pills) cause a lot of attention when they are in public from their appointments (at health facilities). It's not that everyone on (ARV) treatment has accepted their status. It is a relief for those who find it hard going around a bottle of medication.”
In 2019, the Botswana Harvard AIDS Institute conducted clinical trials to determine the efficacy of the injectable drug.
The study proved the drug is safe and highly effective for HIV prevention.
Kennedy Mupeli is a programs officer at Center of Youth for Hope, a non-governmental organization that targets young people living with HIV in Botswana.
With the world's fourth largest prevalence of HIV infections, Botswana becomes the second country in Africa, after South Africa, to adopt the use of the injectable ARV drug. (HN/VOA)
Hurry up! Join the Medical Internship 3.0!